Cellivery Therapeutics, Inc.

KOSDAQ:A268600 Stock Report

Market Cap: ₩244.9b

Cellivery Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of A268600?
Owner TypeNumber of SharesOwnership Percentage
Institutions2,207,6206.02%
Individual Insiders5,147,05414%
General Public29,313,17179.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.

Top Shareholders

Top 17 shareholders own 20.06% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.9%
Daewoong Jo
5,099,454₩34.1b0%no data
2.29%
The Vanguard Group, Inc.
838,278₩5.6b0%no data
1.34%
BlackRock, Inc.
490,504₩3.3b0%no data
1.06%
Samsung Asset Management Co., Ltd.
389,012₩2.6b0%0.01%
0.57%
Norges Bank Investment Management
208,586₩1.4b0%no data
0.33%
Mirae Asset Global Investments Co., Ltd
122,359₩817.4m0%no data
0.12%
Charles Schwab Investment Management, Inc.
45,216₩302.0m0%no data
0.11%
Seonhong Kwon
40,000₩267.2m0%no data
0.1%
State Street Global Advisors, Inc.
37,185₩248.4m0%no data
0.091%
KB Asset Management Co., Ltd.
33,367₩222.9m0%no data
0.078%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
28,469₩190.2m0%no data
0.031%
NH-Amundi Asset Management Co.,Ltd.
11,452₩76.5m6.62%no data
0.021%
Byeonghwa Lee
7,600₩50.8m0%no data
0.0048%
Hanwha Asset Management Co. Ltd.
1,762₩11.8m0%no data
0.0028%
HSBC Global Asset Management (UK) Limited
1,042₩7.0m0%no data
0.00054%
Kyobo AXA Investment Managers Co, Ltd.
198₩1.3m0%no data
0.00052%
Invesco Capital Management LLC
190₩1.3m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/20 12:25
End of Day Share Price 2023/03/23 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellivery Therapeutics, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution